REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

Alert: Replimune shares collapsed from a $10.73 Class Period high to $1.70 following the FDA's rejection of the RP1 biologics license application, a cumulative decline of roughly 84% that the complaint alleges followed disclosures correcting earlier statements about the resubmission. Alert: Replimune shares collapsed from a $10.73 Class Period high to $1.70 following the FDA's rejection of the RP1 biologics license application, a cumulative decline of roughly 84% that the complaint alleges followed disclosures correcting earlier statements about the resubmission.

GlobeNewsWire • 15 hours ago

Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL

San Diego, California--(Newsfile Corp. - August 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies.

Newsfile Corp • 9 hours ago

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026

GlobeNewsWire • 14 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK, Aug. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

GlobeNewsWire • Aug 15, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.

GlobeNewsWire • Aug 14, 2026

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).

GlobeNewsWire • Aug 14, 2026

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR REPLIMUNE GROUP, INC.

GlobeNewsWire • Aug 14, 2026

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

GlobeNewsWire • Aug 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

PRNewsWire • Aug 13, 2026

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action on behalf of shareholders who purchased between October 20, 2025 and April 10, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500. REPL closed at a Class Period high of $10.73 on December 8, 2025. By April 13, 2026, shares closed at $1.70, a cumulative dec.

Business Wire • Aug 13, 2026